Atrion Corp.
Annual Report 2013

Plain-text annual report

ANNUAL REPORT TO STOCKHOLDERS 2013Atrion Corporation develops and manufactures products primarily for medical applications. Our products advance the standard of care by increasing safety for patients and providers. We target niche markets, with particular emphasis on fluid delivery, cardiovascular and ophthalmology applications. Headquartered in Allen, Texas, Atrion has design and manufacturing facilities in Alabama, Florida and Texas. Contents Letter to Stockholders Financial Statements Management’s Discussion Selected Financial Data Corporate Information 2 4 22 27 29 2013Financial Highlights For the Year Ended December 31 2013 2012 As of December 31 2013 2012 Revenues $ 131,993,000 $ 119,062,000 Total Assets $ 172,066,000 $ 155,810,000 Operating Income 37,944,000 33,626,000 Net Income 26,582,000 23,629,000 Cash and Investments 56,979,000 44,614,000 Income per Diluted Share $ 13.18 $ 11.66 Long-term Debt — — Weighted Average Diluted Shares Outstanding 2,017,000 2,027,000 Stockholders’ Equity $ 148,994,000 $ 134,828,000 2009 2010 2011 2012 2013 $8.36 $10.32 $12.82 $11.66 $13.18 2009 2010 2011 2012 2013 $101 $109 $118 $119 $132 2009 2010 2011 2012 2013 $25.0 $31.0 $38.2 $33.6 $37.9 INCOME PER DILUTED SHARE REVENUES (IN MILLIONS) OPERATING INCOME (IN MILLIONS) COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN Among Atrion Corporation, Russell 2000 Index and SIC Code Index Atrion Corporation Russell 2000 Index SIC Code Index 400 300 s r a l l o D 200 100 0 2008 2009 2010 2011 2012 2013 The graph set forth at left compares the total cumulative return for the five-year period ended December 31, 2013 on the Company’s common stock, the Russell 2000 Index and SIC Code 3841 Index-Surgical and Medical Instruments (compiled by Zacks Investment Research, Inc.), assuming $100 was invested on December 31, 2008 in our common stock, the Russell 2000 Index and the SIC Code Index and dividends were reinvested. Company/Index Atrion Corporation Russell 2000 Index SIC Code Index 2008 $100.00 $100.00 $100.00 2009 $162.23 $127.09 $125.01 2010 $199.50 $161.17 $127.90 2011 $269.59 $154.44 $121.00 2012 $233.36 $179.75 $146.20 2013 $356.38 $249.53 $204.47 1 To our stockholders I am pleased to report that 2013 was a year of strong results. All of our major product categories achieved higher revenues compared to 2012, resulting in an overall increase in revenues of 11%, with net income and diluted earnings per share up 13%. We constantly push ourselves to achieve this level of performance. For the last 15 years, the current management team has relentlessly focused on a dedication to developing innovative products, a commitment to—and attainment of—the highest quality standards, and a continual process of seeking and developing talent. The results speak for themselves: annual compounded rates of growth of 8% in sales, 18% in net income—all of which we achieved organically rather than through acquisitions. The Power of Strategic Investments One of our key strengths has been how we’ve chosen to invest in our future. Whether utilizing our cash for technologies to continuously improve our quality and efficiency, or for fortifying our intellectual capital, we’ve kept a steady focus on what it takes to position ourselves for growth. Over the past several years, the foundation we’ve built has consistently allowed us to successfully stay ahead of economic and industry changes, and to deliver impressive results for our stockholders. The success of this capital allocation strategy speaks for itself. In 2013 the after-tax return on equity was 18%, which was stifled by the substantial low-yielding cash and marketable securities that we retain. Excluding these financial assets and the after-tax income they generated, our after-tax return on the equity supporting our business activities was 28%. A Foundation of Our Own Design We have outpaced the growth of the markets in which we participate by cementing customer relationships through exceptional service, and expanding our product offerings and customer base by committing to innovation and quality. While we will remain fully committed to these strategies that have driven our growth, we are also augmenting them to pursue new opportunities. The results speak for themselves: annual compounded rates of growth of 8% in sales, 18% in net income—all of which we achieved organically rather than through acquisitions. 2 ATRION 2013 ANNUAL REPORT For example, many of our largest OEM customers are moving away from funding their own R&D in favor of paying a premium for products that other companies have completed. Few companies are as well-positioned as we are to take advantage of this trend. We have the financial and intellectual resources to create innovative products, the ability to manufacture them properly, and the established OEM relationships through which to sell them. To leverage this opportunity, beginning in 2012 we substantially increased our investments in R&D. Our R&D expenditures are 50% higher than they were in 2011. In addition to our internal projects, we acquired third-party patents, and partnered with outside experts to accelerate our entry into niches we are targeting. Growth through acquisition is also still possible, though our approach to this remains highly disciplined. The valuation must be sensible, and the technology and talent must complement and expand what we have today. Enthusiastic About the Road Ahead Today’s rapid pace of change demands that we stay nimble in order to remain competitive and grow. Our dedication to innovation is aimed at this. In 2014, we will maintain our focus on product development. We expect to continue to show growth in revenues and earnings this year—despite increasing outlays for product development and the uncertain economic outlook in the international markets that are responsible for 42% of our sales. Our success is built on the contributions of many. For their loyalty and effort, I am grateful to our employees. For your continued interest, confidence, and support, I’m deeply appreciative of our stockholders as well. Respectfully, David A. Battat President and Chief Executive Officer 2013 REVENUES BY PRODUCT LINE Fluid Delivery $ 51,289,000 Cardiovascular $ 40,182,000 Ophthalmology $ 20,736,000 Other $ 19,786,000 39% 30% 16% 15% 3 ATRION 2013 ANNUAL REPORT CONSOLIDATED BALANCE SHEETS As of December 31, 2013 and 2012 Assets: Current Assets: Cash and cash equivalents Short-term investments Accounts receivable, net of allowance for doubtful accounts of $86 and $47 in 2013 and 2012, respectively Inventories Prepaid expenses and other current assets Deferred income taxes Total Current Assets Long-term investments Property, Plant and Equipment Less accumulated depreciation and amortization Other Assets and Deferred Charges: Patents and licenses, net of accumulated amortization of $11,032 and $10,853 in 2013 and 2012, respectively Goodwill Other Total Assets The accompanying notes are an integral part of these statements. 2013 2012 (in thousands) $ 28,559 $ 18,351 14,164 26,266 1,603 1,376 90,319 10,069 130,504 72,176 58,328 2,808 9,730 812 13,350 7,999 8,182 13,054 23,779 3,110 623 56,747 28,433 124,180 64,912 59,268 837 9,730 795 11,362 $ 172,066 $ 155,810 4 ATRION 2013 ANNUAL REPORT Liabilities and Stockholders’ Equity: Current Liabilities: Accounts payable Accrued liabilities Accrued income and other taxes Total Current Liabilities Line of credit Other Liabilities and Deferred Credits: Deferred income taxes Other Total Liabilities Commitments and Contingencies Stockholders’ Equity: Common stock, par value $.10 per share, authorized 10,000 shares, issued 3,420 shares Additional paid-in capital Retained earnings Treasury shares, 1,428 shares in 2013, 1,399 shares in 2012, at cost Total Stockholders’ Equity Total Liabilities and Stockholders’ Equity The accompanying notes are an integral part of these statements. 2013 2012 (in thousands) $ 4,088 $ 4,423 853 9,364 — 12,062 1,646 13,708 23,072 3,843 2,900 465 7,208 — 12,232 1,542 13,774 20,982 342 342 31,592 174,362 (57,302) 148,994 29,998 152,630 (48,142) 134,828 $ 172,066 $ 155,810 5 ATRION 2013 ANNUAL REPORT CONSOLIDATED STATEMENTS OF INCOME For the year ended December 31, 2013, 2012 and 2011 Revenues Cost of Goods Sold Gross Profit Operating Expenses: Selling General and administrative Research and development Operating Income Interest Income Other Income, net Income before Provision for Income Taxes Provision for Income Taxes Net Income Net Income Per Basic Share Weighted Average Basic Shares Outstanding Net Income Per Diluted Share Weighted Average Diluted Shares Outstanding Dividends Per Common Share The accompanying notes are an integral part of these statements. 2013 2012 2011 (in thousands, except per share amounts) $ 131,993 $ 119,062 $ 117,704 68,931 63,062 6,218 14,612 4,288 25,118 37,944 1,313 8 62,922 56,140 5,694 13,054 3,766 22,514 33,626 1,447 2 57,697 60,007 5,325 13,646 2,868 21,839 38,168 1,295 12 39,265 (12,683) 35,075 (11,446) 39,475 (13,437) 26,582 $ 23,629 $ 26,038 13.22 $ 11.72 $ 2,010 2,016 13.18 $ 11.66 $ 2,017 2,027 2.40 $ 12.10 $ 12.90 2,019 12.82 2,031 1.82 $ $ $ $ 6 ATRION 2013 ANNUAL REPORT CONSOLIDATED STATEMENTS OF CASH FLOWS For the year ended December 31, 2013, 2012 and 2011 Cash Flows From Operating Activities: Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Deferred income taxes Stock-based compensation Net change in accrued interest, premiums, and discounts on investments Other Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses and other current assets Other non-current assets Accounts payable and accrued liabilities Accrued income and other taxes Other non-current liabilities Cash Flows From Investing Activities: Property, plant and equipment additions Purchase of patents Purchase of investments Proceeds from maturities of investments Cash Flows From Financing Activities: Exercise of stock options Shares tendered for employees’ withholding taxes on stock-based compensation Tax benefit related to stock-based compensation Purchase of treasury stock Dividends paid Net change in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Cash paid for: Income taxes The accompanying notes are an integral part of these statements. 2013 2012 2011 (in thousands) $ 26,582  $ 23,629  $ 26,038  8,592  (923) 1,586  556  30 7,610  1,462  1,482  817  — 6,544  2,584  1,047  824  — 36,423  35,000  37,037  (1,110) (2,487) 1,507  (17) 1,768  388  104  36,576  (7,503) (2,150) — 7,639  (2,014) —  — 15  (9,196) (4,821) (14,002) 20,560  7,999  (1,831) 803  (797) (77) (2,465) (370) (894) 29,369  298  (7,182) (1,263) 18  2,008  283  341  31,540  (10,347) (11,999) — — (26,566) 19,750  (17,163) 731  (1,136) 1,412  (5,344) (24,460) (28,797) (16,591) 24,590  (14,723) 14,290  (12,432) —  (78) 79  (1,513) (3,676) (5,188) 13,920  10,670  $ 28,559  $ 7,999  $ 24,590  $ 8,036  $ 10,357  $ 11,921  7 ATRION 2013 ANNUAL REPORT CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY For the year ended December 31, 2013, 2012, and 2011 (in thousands) Common Stock Treasury Stock Shares Outstanding Amount Shares Amount Additional Paid-in Capital Retained Earnings Total Balances, January 1, 2011 2,016  $ 342 1,404  $ (39,342) $ 24,331 $ 131,286 $ 116,617  26,038 26,038  Net income Tax benefit from stock-based compensation Stock-based compensation transactions Shares surrendered in stock transactions Purchase of treasury stock Dividends 8  (8) (8) 8  35  (78) (1,513) 79 1,042 (3,706) Balances, December 31, 2011 2,016  342 1,404  (40,898) 25,452 153,618 Net income Tax benefit from stock-based compensation Stock-based compensation transactions Shares surrendered in stock transactions Purchase of treasury stock Dividends 41  (9) (27) (41) 9  27  368  (2,268) (5,344) 1,412 3,134 23,629 (24,617) Balances, December 31, 2012 2,021  342 1,399  (48,142) 29,998 152,630 Net income Tax benefit from stock-based compensation Stock-based compensation transactions Purchase of treasury stock Dividends 1  (30) (1) 30  36  (9,196) 15 1,579 26,582 (4,850) 79  1,077  (78) (1,513) (3,706) 138,514  23,629  1,412  3,502  (2,268) (5,344) (24,617) 134,828  26,582  15  1,615  (9,196) (4,850) Balances, December 31, 2013 1,992  $ 342 1,428  $ (57,302) $ 31,592 $ 174,362 $ 148,994  The accompanying notes are an integral part of these statements. 8 ATRION 2013 ANNUAL REPORT ATRION CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (1) Summary of Significant Accounting Policies Atrion Corporation and its subsidiaries (“we,” “our,” “us,” “Atrion” or the “Company”) develop and manufacture products primarily for medical applications. We market our products throughout the United States and internationally. Our customers include hospitals, distributors, and other manufacturers. Atrion Corporation’s principal subsidiaries through which these operations are conducted are Atrion Medical Products, Inc., Halkey-Roberts Corporation and Quest Medical, Inc. Principles of Consolidation The consolidated financial statements include the accounts of Atrion Corporation and its subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Cash and Cash Equivalents Cash equivalents include cash on hand and in the bank as well as money market accounts and debt securities with original maturities of 90 days or less. Trade Receivables Trade accounts receivable are recorded at the original sales price to the customer. We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts. We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with appropriate Company personnel and with the customers directly. Accounts are written off when we determine the receivable will not be collected. Investments Our investments consist of taxable corporate bonds. Our investment policy is to seek to preserve principal and maintain adequate liquidity while at the same time maximizing yields without significantly increasing risk. We are required to classify our investments as trading, available-for-sale or held-to- maturity. Our investments are accounted for as held-to-maturity since we have the positive intent and ability to hold these investments to maturity. These investments are reported at cost, adjusted for premiums and discounts that are recognized in interest income, using a method that approximates the effective interest method, over the period to maturity and unrealized gains and losses are excluded from earnings. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets. 9 Notes to Consolidated Financial Statements ATRION 2013 ANNUAL REPORT Inventories Inventories are stated at the lower of cost (including materials, direct labor and applicable overhead) or market. Cost is determined by using the first-in, first-out method. The following table details the major components of inventory (in thousands): December 31, 2013 2012 Raw materials Work in process Finished goods Total inventories $ $ 10,744 $ 6,246 9,276 26,266 $ 10,017 5,268 8,494 23,779 Accounts Payable We reflect disbursements as trade accounts payable until such time as payments are presented to our bank for payment. At December 31, 2013 and 2012, disbursements totaling approximately $443,000 and $495,000, respectively, had not been presented for payment to our bank. Income Taxes We account for income taxes utilizing Accounting Standards Codification (ASC) 740, Income Taxes (“ASC 740”). ASC 740 requires the asset and liability method for the recording of deferred income taxes, whereby deferred tax assets and liabilities are recognized based on the tax effects of temporary differences between the financial statement and the tax bases of assets and liabilities, as measured at current enacted tax rates. When appropriate, we evaluate the need for a valuation allowance to reduce deferred tax assets. ASC 740 also requires the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attributes of income tax positions taken or expected to be taken on a tax return. Under ASC 740, the impact of an uncertain tax position taken or expected to be taken on an income tax return must be recognized in the financial statements at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more-likely-than-not of being sustained. Our uncertain tax positions are recorded as “Other non-current liabilities.” We classify interest expense on underpayments of income taxes and accrued penalties related to unrecognized tax benefits in the income tax provision. Property, Plant and Equipment Property, plant and equipment is stated at cost and depreciated using the straight-line method over the estimated useful lives of the related assets. Additions and improvements are capitalized, including all material, labor and engineering costs to design, install or improve the asset. Expenditures for repairs and maintenance are charged to expense as incurred. The following table represents a summary of property, plant and equipment at original cost (in thousands): December 31, 2013 2012 Useful Lives $ 5,260 $ 31,314 5,260 30,664 — 30-40 yrs 93,930 88,256 3-15 yrs $ 130,504 $ 124,180 Land Buildings Machinery and equipment Total property, plant and equipment Depreciation expense of $8,413,000, $7,448,000 and $6,272,000 was recorded for the years ended December 31, 2013, 2012 and 2011, respectively. Depreciation expense is recorded in either cost of goods sold or operating expenses based on the associated assets’ usage. Patents and Licenses Costs for patents and licenses acquired are determined at acquisition date. Patents and licenses are amortized over the useful lives of the individual patents and licenses, which are from 7 to 20 years. Patents and licenses are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Goodwill Goodwill represents the excess of cost over the fair value of tangible and identifiable intangible net assets acquired. Annual impairment testing for goodwill is done using a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test. Goodwill is also reviewed whenever events or changes in circumstances indicate a change in value may have occurred. We have identified three reporting units where goodwill was recorded for purposes of testing goodwill impairment annually: (1) Atrion Medical Products, Inc., (2) Halkey-Roberts Corporation and (3) Quest Medical, Inc. The total carrying amount of goodwill in each of the years ended December 31, 2013, 2012 and 2011 was $9,730,000. Our evaluation of goodwill during the year resulted in no impairment losses. 10 ATRION 2013 ANNUAL REPORT Notes to Consolidated Financial StatementsCurrent Accrued Liabilities The items comprising current accrued liabilities are as follows (in thousands): December 31, 2013 2012 Accrued payroll and related expenses $  3,711  $  2,276  Accrued vacation Other accrued liabilities Total accrued liabilities 229  483  210  414  $  4,423  $  2,900  Revenues We recognize revenue when our products are shipped to our customers, provided an arrangement exists, the fee is fixed and determinable and collectability is reasonably assured. All risks and rewards of ownership pass to the customer upon shipment. Net sales represent gross sales invoiced to customers, less certain related charges, including discounts, returns and other allowances. Revenues are recorded exclusive of sales and similar taxes. Returns, discounts and other allowances have been insignificant historically. Shipping and Handling Policy Shipping and handling fees charged to customers are reported as revenue and all shipping and handling costs incurred related to products sold are reported as cost of goods sold. Research and Development Costs Research and development costs relating to the development of new products and improvements of existing products are expensed as incurred. Stock-Based Compensation We have stock-based compensation plans covering certain of our officers, directors and key employees. As explained in detail in Note 8, we account for stock-based compensation utilizing the fair value recognition provisions of ASC 718, Compensation- Stock Compensation, (“ASC 718”). New Accounting Pronouncements From time to time, new accounting pronouncements applicable to us are issued by the Financial Accounting Standards Board (“FASB”) or other standards setting bodies, which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption. Fair Value Measurements Accounting standards use a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers are: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists therefore requiring an entity to develop its own assumptions. As of December 31, 2013 and 2012, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis. These investments are considered Level 2 assets. The fair value of our investments is estimated using recently executed transactions and market price quotations. At December 31, 2013 and 2012, the fair value of our investments approximated or exceeded the carrying value of the investments (see Note 2). The carrying values of our other financial instruments including cash and cash equivalents, money market accounts, accounts receivable, accounts payable, accrued liabilities, and accrued income and other taxes approximated fair value due to their liquid and short-term nature. Concentration of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, investments and accounts receivable. Our cash is held in high credit quality financial institutions. As of December 31, 2013, we had $28.6 million in cash and cash equivalents invested as follows: $2.6 million invested in money market mutual funds and $26.0 million held in depository accounts. From time to time, deposits held with financial institutions exceed the amount of Federal Deposit Insurance Corporation, or FDIC, insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. At December 31, 2013, our uninsured cash and cash equivalents totaled approximately $27.0 million. For accounts receivable, we perform ongoing credit evaluations of our customers’ financial condition and generally do not require collateral. We maintain reserves for possible credit losses. As of December 31, 2013 and 2012, we had allowances for doubtful accounts of approximately $86,000 and $47,000, respectively. The carrying amount of the receivables approximates their fair value. Our customer that generates our largest revenues accounted for 8.2%, 16.3% and 6.7% of accounts receivable as of December 31, 2013, 2012 and 2011, respectively. No other customer exceeded 10% of our accounts receivable as of December 31, 2013, 2012 or 2011. 11 Notes to Consolidated Financial Statements ATRION 2013 ANNUAL REPORT (2) Investments As of December 31, 2013 and 2012, we held certain investments that were required to be measured for disclosure purposes at fair value on a recurring basis. These investments were considered Level 2 investments. We consider as current assets those investments which will mature in the next 12 months. The remaining investments are considered non-current assets. The amortized cost and fair value of our investments that are being accounted for as held-to- maturity securities, and the related gross unrealized gains and losses, were as follows as of the dates shown below (in thousands): (3) Patents and Licenses Purchased patents and licenses paid for the use of other entities’ patents are amortized over the useful life of the patent or license. The following tables provide information regarding patents and licenses (dollars in thousands): December 31, 2013 Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization 18.55 $ 13,840 $ 11,032 Gross Unrealized Cost Gains Losses As of December 31, 2013 December 31, 2012 Fair Value Weighted Average Original Life (years) Gross Carrying Amount Accumulated Amortization 14.88 $ 11,690 $ 10,853 Short-term Investments: Corporate bonds $ 18,351 $ 234 $ — $ 18,585 Long-term Investments: Corporate bonds $ 10,069 $ 285 $ — $ 10,354 Aggregate amortization expense for patents and licenses was $179,000 for 2013, $162,000 for 2012 and $272,000 for 2011. Estimated future amortization expense for each of the years set forth below ending December 31, is as follows (in thousands): As of December 31, 2012 Short-term Investments: Corporate bonds $ 8,182 $ 78 $ — $ 8,260 Long-term Investments: Corporate bonds $ 28,433 $ 652 $ 29 $ 29,056 At December 31, 2013, the length of time until maturity of these securities ranged from five to 16 months. 2014 2015 2016 2017 2018 $ $ $ $ $ 269 269 269 173 141 (4) Line of Credit We have a revolving credit facility with a money center bank which is secured by substantially all our inventories, equipment and accounts receivable. Effective October 1, 2011, our credit facility was amended to increase the maximum principal amount of our revolving line of credit from $25.0 million to $40.0 million. Interest under the credit facility is assessed at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent (1.17 percent at December 31, 2013) and is payable monthly. We had no outstanding borrowings under the credit facility at December 31, 2013 or 2012. The credit facility amendment also extended the date on which the lender is obligated to make advances under the revolving line of credit to October 1, 2016. At any time during the term, we may convert any or all outstanding amounts under the credit facility to a term loan with a maturity of two years. Our ability to borrow funds under the credit facility from time to time is contingent on meeting certain covenants in the loan agreement, the most restrictive of which is the ratio of total debt to earnings before interest, income tax, depreciation and amortization. At December 31, 2013, we were in compliance with all of those covenants. 12 ATRION 2013 ANNUAL REPORT Notes to Consolidated Financial Statements(5) Income Taxes The items comprising income tax expense are as follows (in thousands): Total income tax expense differs from the amount that would be provided by applying the statutory federal income tax rate to pretax earnings as illustrated below (in thousands): Year ended December 31, 2013 2012 2011 Current — Federal $ 12,541  $ 8,934 $ 9,973 Current — State Deferred — Federal Deferred — State 1,065  13,606  (1,063) 140  (923) 1,050 9,984 1,363 99  1,462 880 10,853 2,372 212 2,584 Total income tax expense $ 12,683  $ 11,446 $ 13,437 Temporary differences and carryforwards which have given rise to deferred income tax assets and liabilities as of December 31, 2013 and 2012 are as follows (in thousands): 2013 2012 $ 1,590 $ 1,099 525 37 536 38 2,152 $ 1,673 9,716 $ 10,299 2,956 166 2,972 11 12,838 $ 13,282 10,686 $ 11,609 $ $ $ $ Deferred tax assets: Benefit plans Inventories Other Total deferred tax assets Deferred tax liabilities: Property, plant and equipment Patents and goodwill Other Total deferred tax liabilities Net deferred tax liability Balance Sheet classification: Non-current deferred income tax liability Year ended December 31, 2013 2012 2011 $ 13,743  $ 12,276  $ 13,816  Income tax expense at the statutory federal income tax rate Increase (decrease) resulting from: State income taxes 770  747  710  Section 199 manufacturing deduction Other, net Total income tax expense (1,307) (523) (949) (628) (996) (93) $ 12,683  $ 11,446  $ 13,437  A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized tax benefits as required by ASC 740 is as follows (in thousands): Gross unrecognized tax benefits at January 1, 2011 $ 1,420  Decreases in tax positions for prior years Increases in tax positions for current year Lapse in statutes of limitation (77) 134  (216) Gross unrecognized tax benefits at December 31, 2011 $ 1,261  Increase in tax positions for prior years Increase in tax positions for current year Decrease due to settlement with taxing authorities Lapse in statutes of limitation Gross unrecognized tax benefits at December 31, 2012 $ Increase in tax positions for prior years Current deferred income tax asset 1,376 623 Lapse in statutes of limitation Net deferred tax liability $ 10,686 $ 11,609 Gross unrecognized tax benefits at December 31, 2013 $ $ 12,062 $ 12,232 Increase in tax positions for current year 19  0  (641) (98) 541  11  0  (206) 346  13 Notes to Consolidated Financial Statements ATRION 2013 ANNUAL REPORT As of December 31, 2013 all of the unrecognized tax benefits, which were comprised of uncertain tax positions, would impact the effective tax rate if recognized. Unrecognized tax benefits that are affected by statutes of limitation that expire within the next 12 months are immaterial. We are subject to United States federal income tax as well as to income tax of multiple state jurisdictions. We have concluded all United States federal income tax matters for years through 2009. In January 2009, the Internal Revenue Service (“IRS”) began examining certain of our United States federal income tax returns for 2006, 2007 and 2008. This audit was favorably concluded in the third quarter of 2012 when the IRS appeals group allowed 100% of the tax credits claimed for our research and development during those years. Our unrecognized tax benefits were reduced at that time on the basis of this favorable settlement in the amount of approximately $641,000. All material state and local income tax matters have been concluded for years through 2009. We recognize interest and penalties, if any, related to unrecognized tax benefits in income tax expense. The liability for unrecognized tax benefits included accrued interest of $21,000, $26,000 and $77,000 at December 31, 2013, 2012 and 2011, respectively. Tax expense for the year ended December 31, 2013, 2012 and 2011 included a net interest benefit of $5,400, $51,000 and $7,000, respectively. (6) Stockholders’ Equity Our Board of Directors has at various times authorized repurchases of our stock in open-market or negotiated transactions at such times and at such prices as management may from time to time determine. On August 16, 2011, our Board of Directors adopted a new stock repurchase program pursuant to which we can repurchase up to 200,000 shares of our common stock from time to time in open market or privately- negotiated transactions. This stock repurchase program has no expiration date but may be terminated by the Board of Directors at any time. As of December 31, 2012, 165,438 shares remained available for repurchase under this program. In 2013, we repurchased 36,666 shares under this program, including 6,704 shares from executive officers in transactions during an open window period for trading, and that were pre-cleared, under our Insider Trading Policy. In 2012 and 2011, we repurchased 26,562 and 8,000 shares, respectively, and as of December 31, 2013 there remained 128,772 shares available for repurchase under the program. We have increased our quarterly cash dividend payments in September of each of the past three years. The quarterly dividend was increased to $.49 per share in September 2011, to $.56 per share in September 2012 and to $.64 in September 2013. On December 10, 2012 we also paid a special cash 14 dividend to stockholders of $10.00 per share. Holders of stock units earned non-cash dividends of $29,000 in 2013, $157,000 in 2012 and $30,000 in 2011. We have a Rights Plan, which is intended to protect the interests of stockholders in the event of a hostile attempt to take over the Company. The rights, which are not presently exercisable and do not have any voting powers, represent the right of our stockholders to purchase at a substantial discount, upon the occurrence of certain events, shares of our common stock or of an acquiring company involved in a business combination with us. This plan, which was adopted in August 2006, expires in August 2016. (7) Income Per Share The following is the computation of basic and diluted income per share: Year ended December 31, 2013 2012 2011 (in thousands, except per share amounts) Net Income $ 26,582 $ 23,629 $ 26,038 Weighted average basic shares outstanding Add: Effect of dilutive securities Weighted average diluted shares outstanding Net Income Per Share 2,010 2,016 2,019 7 11 12 2,017 2,027 2,031 Basic Diluted $ $ 13.22 13.18 $ $ 11.72 $ 11.66 $ 12.90 12.82 As required by ASC 260, Earnings per Share, unvested share- based payment awards that contain non-forfeitable rights to dividends or dividend equivalents are considered participating securities and, therefore, are included in the computation of basic income per share pursuant to the two-class method. Incremental shares from stock options and restricted stock units were included in the calculation of weighted average diluted shares outstanding using the treasury stock method. Dilutive securities representing 4,344 shares of common stock for the year ended December 31, 2013 were excluded from the computation of weighted average diluted shares outstanding because their effect would have been anti-dilutive. (8) Stock Plans At December 31, 2013, we had three stock-based compensation plans which are described more fully below. We account for our plans under ASC 718, and the disclosures that follow are based ATRION 2013 ANNUAL REPORT Notes to Consolidated Financial Statementson applying ASC 718. ASC 718 requires that cash flows from the use of stock-based compensation resulting from tax benefits in excess of recognized compensation cost (excess tax benefits) be classified as financing cash flows. We recorded $15,000, $1,412,000 and $79,000 of such excess tax benefits as financing cash flows in 2013, 2012 and 2011, respectively. Our Amended and Restated 2006 Equity Incentive Plan (the “2006 Plan”) provides for the grant to key employees, non- employee directors and consultants of incentive and nonqualified stock options, restricted stock, restricted stock units, deferred stock units, stock appreciation rights, performance shares and other stock-based awards. Under the 2006 Plan, 200,000 shares, in the aggregate, of common stock have been reserved for awards. The purchase price of shares issued on the exercise of options must be at least equal to the fair market value of such shares on the date of grant. The options granted become exercisable and expire as determined by the Compensation Committee. As of December 31, 2013, there remained 58,242 shares for future stock-based awards under the 2006 Plan. In May 2007, we adopted our Deferred Compensation Plan for Non-Employee Directors (as amended, the “Deferred Compensation Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. This plan allows our non-employee directors to elect to receive stock units in lieu of all or part of the cash fees they are receiving for their services as directors. On the first business day of each calendar year, each participating non-employee director is credited with a number of stock units determined on the basis of the foregone cash fees and the closing price of our common stock on the next preceding date on which shares of our stock were traded. The stock units are converted to shares of our common stock on a one-for-one basis at a future date as elected in advance by the director, but no later than the January following the year in which the director ceases to serve on the Board of Directors, and the shares are delivered to the director. As of December 31, 2013, there remained 1,626 shares of common stock reserved for issuance upon the conversion of stock units which may be credited in the future to non-employee directors. In May 2007, we also adopted our Non-Employee Director Stock Purchase Plan, (as amended, the “Director Stock Purchase Plan”), and 2,500 shares of our common stock were initially reserved for issuance thereunder. Under this plan, our non-employee directors may elect to receive on the first business day of the calendar year fully-vested stock and restricted stock in lieu of some or all of their fees payable to them during such year. The foregone fees are converted into shares of fully-vested stock and restricted stock on the first business day of such calendar year based on the closing price of our common stock on the next preceding date on which shares of our stock were traded. The restricted stock vests in equal amounts on the first day of the next three succeeding calendar quarters provided the non-employee director is then serving on our Board of Directors. As of December 31, 2013, there remained 1,126 shares reserved for issuance under such plan. A summary of stock option transactions for the year ended December 31, 2013 is presented below: Options Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Outstanding at December 31, 2012 Granted Exercised Outstanding at December 31, 2013 Exercisable at December 31, 2013 50,000  $ 204.76 —  — — — 50,000  $ 204.76 4.9 years 15,000  $ 196.99 4.7 years All nonvested options outstanding at December 31, 2013 are expected to vest. We estimate the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. None of our grants includes performance-based or market-based vesting conditions. The expected life represents the period that our stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. The fair value of stock-based payments, funded with options, is valued using the Black-Scholes valuation method with a volatility factor based on our historical stock trading history. We base the risk-free interest rate using the Black-Scholes valuation method on the implied yield currently available on U.S. Treasury securities with an equivalent term. We base the dividend yield used in the Black-Scholes valuation method on our dividend history. There were no options granted in 2013. The fair value for the options granted in 2012 and 2011 was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions: Risk-free interest rate Dividend yield Volatility factor Expected life 2013 2012 2011 — — — — 0.5% 1.0% 25.0% 5 years 1.7% 1.0% 25.0% 5 years 15 Notes to Consolidated Financial Statements ATRION 2013 ANNUAL REPORT The weighted average grant date fair value of the options granted in 2012 and 2011 was $40.38 and $40.64, respectively. The total intrinsic value of options exercised during 2012 was $3.1 million. There were no options exercised in 2013 and 2011. The total intrinsic values of options outstanding and options currently exercisable at December 31, 2013, were $4.6 million and $1.5 million, respectively. During 2013, we made no awards of restricted stock under the 2006 Plan. Under the terms of our restricted stock awards, the restrictions usually lapse over a five-year period. During the vesting period, holders of restricted stock have voting rights and earn dividends, but the shares may not be sold, assigned, transferred, pledged or otherwise encumbered. Nonvested shares are generally forfeited on termination of employment unless otherwise provided in the participant’s employment agreement or the termination is in connection with a change in control. A summary of changes in nonvested restricted stock for the year ended December 31, 2013 is presented below: Nonvested Shares Shares Weighted Average Award Date Fair Value Per Share Restricted stock at December 31, 2012 13,500  $ 207.35 Granted in 2013 Vested in 2013 — $ (3,000) $ Restricted stock at December 31, 2013 10,500  $ — 211.06 208.09 All shares of nonvested restricted stock outstanding at December 31, 2013 are expected to vest. The total fair value of restricted stock vested during 2013, 2012 and 2011 was $633,000, $559,000 and $481,000, respectively. During 2013, restricted stock units were awarded to certain employees under the 2006 Plan. All of our restricted stock units are convertible to shares of stock on a one-for-one basis when the restrictions lapse, which is generally after a five-year period. Nonvested stock units are generally forfeited on termination of employment unless the termination is in connection with a change in control. During the vesting period, holders of all restricted stock units earn dividends in the form of additional units. During 2013, one non-employee director elected to receive stock units in lieu of a portion of his cash fees for his services as a member of the Board of Directors. A summary of changes in stock units for the year ended December 31, 2013, is presented below: Weighted Average Award Date Fair Value Per Unit Restricted Stock Units Director’s Stock Units Weighted Average Award Date Fair Value Per Unit 11,996  908  — $ $  194.95  214.76 —  41  $ 199.78 — (41) $ 199.78 12,904  $  196.35 —  Nonvested Stock Units Nonvested at December 31, 2012 Granted Vested Nonvested at December 31, 2013 All nonvested restricted stock units at December 31, 2013 are expected to vest. The total intrinsic value of all outstanding stock units which were not convertible at December 31, 2013, including 389 stock units held for the accounts of non-employee directors, was $3,938,000. There were no vested restricted stock units during 2013. The total fair value of directors’ stock units vested during 2013, 2012 and 2011 was $8,000, $22,000 and $8,000, respectively. Stock awards that vest immediately were awarded under the 2006 Plan to non-employee directors in 2013, 2012 and 2011 totaling $120,000 in value in each year. Compensation related to stock awards, restricted stock and stock units is based on the fair market value of the stock on the date of the grant. These fair values are then amortized on a straight-line basis over the requisite service periods of the entire awards, which is generally the vesting period. Compensation related to stock options is based on the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. For the years ended December 31, 2013, 2012 and 2011, we recorded stock-based compensation expense as a “General and Administrative expense” in the amount of $1,586,000, $1,482,000 and $1,047,000, respectively, for all of the above mentioned stock-based compensation arrangements. The total tax benefit recognized in the income statement from stock-based compensation arrangements for the years ended December 31, 2013, 2012 and 2011, was $555,000, $516,000 and $359,000, respectively. 16 ATRION 2013 ANNUAL REPORT Notes to Consolidated Financial StatementsUnrecognized compensation cost information for our various stock-based compensation types is shown below as of December 31, 2013: A summary of revenues by product line for 2013, 2012 and 2011 is as follows (in thousands): Unrecognized Compensation Cost $ 1,172,000 1,812,000 1,355,000 Weighted Average Remaining Years in Amortization Period 3.0 3.0 3.3 Fluid Delivery Cardiovascular Ophthalmology Other Total Stock options Restricted stock Restricted stock units 2013 2012 2011 $ 51,289 $ 49,060 $ 45,274 40,182 20,736 19,786 36,021 15,717 18,264 34,072 19,581 18,777 $ 131,993 $ 119,062 $ 117,704 Total $ 4,339,000 We have a policy of utilizing treasury shares to satisfy stock option exercises, stock unit conversions and restricted stock awards. (9) Revenues From Major Customers We had one major customer which represented approximately $13.5 million (10.2 percent) and $15.1 million (12.9 percent) of our net revenues during 2013 and 2011, respectively. (10) Industry Segment and Geographic Information We operate in one reportable industry segment: developing and manufacturing products primarily for medical applications and have no foreign operating subsidiaries. We have other product lines which include pressure relief valves and inflation systems, which are sold primarily to the aviation and marine industries. Due to the similarities in product technologies and manufacturing processes, these products are managed as part of our medical products segment. Our revenues from sales to customers outside the United States totaled approximately 42 percent of our net revenues in 2013, 2012 and 2011. We have no assets located outside the United States. A summary of revenues by geographic territory, based on shipping destination, for 2013, 2012 and 2011 is as follows (in thousands): Year ended December 31, 2013 2012 2011 (11) Employee Retirement and Benefit Plans We sponsor a defined contribution 401(k) plan for all employees. Each participant may contribute certain amounts of eligible compensation. We make a matching contribution to the plan. Our contributions under this plan were $561,000, $533,000 and $487,000 in 2013, 2012 and 2011, respectively. (12) Commitments and Contingencies From time to time and in the ordinary course of business, we may be subject to various claims, charges and litigation. In some cases, the claimants may seek damages, as well as other relief, which, if granted, could require significant expenditures. We accrue the estimated costs of settlement or damages when a loss is deemed probable and such costs are estimable, and accrue for legal costs associated with a loss contingency when a loss is probable and such amounts are estimable. Otherwise, these costs are expensed as incurred. If the estimate of a probable loss or defense costs is a range and no amount within the range is more likely, we accrue the minimum amount of the range. As of December 31, 2013, the Company had no ongoing litigation or arbitration for such matters. We had a dispute which was favorably settled in the third quarter of 2007. This settlement was amended in December 2008. The amended settlement agreement provides that we may receive annual payments from 2009 through 2024. We have not recorded $5.5 million in potential future payments under this settlement as of December 31, 2013 due to the uncertainty of payment. United States $ 75,997 $ 69,388 $ 68,156 Canada 15,114 13,352 17,524 Other countries less than 10% of revenues 40,882 36,322 32,024 Total $ 131,993 $ 119,062 $ 117,704 We have arrangements with three of our executive officers pursuant to which the termination of their employment under certain circumstances would result in lump sum payments to them. Termination under such circumstances at December 31, 2013 could have resulted in payments aggregating $4.3 million. 17 Notes to Consolidated Financial Statements ATRION 2013 ANNUAL REPORT (13) Quarterly Financial Data (Unaudited) Quarter Ended Operating Revenue Operating Income Net Income (in thousands, except per share amounts) Income Per Basic Share Income Per Diluted Share 03/31/13 06/30/13 09/30/13 12/31/13 03/31/12 06/30/12 09/30/12 12/31/12 $ 33,493 $ 9,400 $ 6,635 $ 3.28 $ 32,605 34,044 31,851 9,495 10,713 8,336 6,506 7,673 5,768 3.23 3.82 2.88 $ 29,239 $ 7,943 $ 5,377 $ 2.67 $ 30,689 30,637 28,497 8,967 9,677 7,039 6,099 7,259 4,894 3.03 3.60 2.42 3.28 3.22 3.81 2.87 2.65 3.02 3.59 2.42 The quarterly information presented above reflects, in the opinion of management, all adjustments necessary for a fair presentation of the results for the interim periods presented. 18 ATRION 2013 ANNUAL REPORT Notes to Consolidated Financial StatementsREPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders Atrion Corporation We have audited the accompanying consolidated balance sheets of Atrion Corporation and subsidiaries (the “Company”) as of December 31, 2013 and 2012, and the related consolidated statements of income, changes in stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2013. Our audits of the basic consolidated financial statements included the financial statement schedule (not presented separately herein) listed in the index appearing under Item 15. Exhibits and Financial Statement Schedules. These financial statements and financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and financial statement schedule based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Atrion Corporation and subsidiaries as of December 31, 2013 and 2012, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2013 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material aspects, the information set forth therein. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), Atrion Corporation and subsidiaries’ internal control over financial reporting as of December 31, 2013, based on criteria established in the 1992 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and our report dated March 14, 2014 expressed an unqualified opinion. Grant Thornton LLP Dallas, Texas March 14, 2014 Report of Independent Registered Public Accounting Firm ATRION 2013 ANNUAL REPORT 19 MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2013 using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in the 1992 Internal Control—Integrated Framework. Based on this assessment, our management concluded that, as of December 31, 2013, our internal control over financial reporting was effective. Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. All internal control systems, no matter how well designed, have inherent limitations. A system of internal control may become inadequate over time because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. 20 ATRION 2013 ANNUAL REPORT Management’s Report on Internal Control Over Financial Reporting REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Board of Directors and Stockholders Atrion Corporation We have audited the internal control over financial reporting of Atrion Corporation and subsidiaries (the “Company”) as of December 31, 2013, based on criteria established in the 1992 Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2013, based on criteria established in the 1992 Internal Control—Integrated Framework issued by COSO. We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements of the Company as of and for the year ended December 31, 2013, and our report dated March 14, 2014, expressed an unqualified opinion on those financial statements. Grant Thornton LLP Dallas, Texas March 14, 2014 Report of Independent Registered Public Accounting Firm ATRION 2013 ANNUAL REPORT 21  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the year ended December 31, 2013, we reported revenues of $132.0 million, operating income of $37.9 million and net income of $26.6 million. Results of Operations Our net income was $26.6 million, or $13.22 per basic and $13.18 per diluted share, in 2013, compared to net income of $23.6 million, or $11.72 per basic and $11.66 per diluted share, in 2012 and net income of $26.0 million, or $12.90 per basic and $12.82 per diluted share, in 2011. Revenues were $132.0 million in 2013, compared with $119.1 million in 2012 and $117.7 million in 2011. The 11 percent revenue increase in 2013 over 2012 and 1 percent revenue increase in 2012 over 2011 were generally attributable to higher sales volumes. Increases in revenues in 2012 in our fluid delivery and cardiovascular product lines were largely offset by reduced ophthalmology sales to a large customer with which we have a long-term contract that had accumulated too large of an inventory of one of our products in 2011. Annual revenues by product lines were as follows (in thousands): Fluid Delivery Cardiovascular Ophthalmology Other Total 2013 2012 2011 $ 51,289 $ 49,060 $ 45,274 40,182 20,736 19,786 36,021 15,717 18,264 34,072 19,581 18,777 $ 131,993 $ 119,062 $ 117,704 Overview We develop and manufacture products primarily for medical applications. We market components to other equipment manufacturers for incorporation in their products and sell finished devices to physicians, hospitals, clinics and other treatment centers. Our medical products primarily serve the fluid delivery, cardiovascular, and ophthalmology markets. Our other medical and non-medical products include valves and inflation devices used in marine and aviation safety products. In 2013, approximately 42 percent of our sales were outside the United States. Our products are used in a wide variety of applications by numerous customers. We encounter competition in all of our markets and compete primarily on the basis of product quality, price, engineering, customer service and delivery time. Our strategy is to provide a broad selection of products in the areas of our expertise. Research and development efforts are focused on improving current products and developing highly-engineered products that meet customer needs and serve niche markets with meaningful sales potential. Proposed new products may be subject to regulatory clearance or approval prior to commercialization and the time period for introducing a new product to the marketplace can be unpredictable. We also focus on controlling costs by investing in modern manufacturing technologies and controlling purchasing processes. We have been successful in consistently generating cash from operations and have used that cash to reduce or eliminate indebtedness, to fund capital expenditures, to make investment purchases, to repurchase stock and to pay dividends. Our strategic objective is to further enhance our position in our served markets by: Focusing on customer needs; Expanding existing product lines and developing new products; Maintaining a culture of controlling cost; and Preserving and fostering a collaborative, entrepreneurial management structure. 22 ATRION 2013 ANNUAL REPORT Management’s Discussion and Analysis of Financial Condition and Results of Operations Our cost of goods sold was $68.9 million in 2013, $62.9 million in 2012 and $57.7 million in 2011. Higher sales volume was the primary contributor to the increase in cost of goods sold in 2013 over 2012. Product mix, higher depreciation expense and lower manufacturing efficiencies offset by the impact of continued cost improvement initiatives were the primary contributors to the 10 percent increase in cost of goods sold for 2012 over 2011. Gross profit in 2013 was $63.1 million compared with $56.1 million in 2012 and $60.0 million in 2011. Our gross profit was 48 percent of revenues in 2013, 47 percent of revenues in 2012 and 51 percent of revenues in 2011. The increase in gross profit percentage in 2013 over 2012 was primarily related to a product mix that was more favorable than 2012’s product mix, improvements in manufacturing efficiencies and the impact of cost-savings projects partially offset by the new 2.3 percent excise tax on the sale of certain medical devices in the United States. The decrease in gross profit percentage in 2012 from the prior year was primarily due to a less favorable product mix and reduced manufacturing capacity utilization. Operating expenses were $25.1 million in 2013 compared with $22.5 million in 2012 and $21.8 million in 2011. Research and development, or R&D, expenses increased $522,000 in 2013 as compared to 2012 primarily related to increased costs for supplies, outside services and compensation, partially offset by decreased travel costs. R&D expenses consist primarily of salaries and other related expenses of our R&D personnel as well as costs associated with regulatory matters. In 2013, selling expenses increased $524,000 primarily related to increased outside services, compensation, commissions and promotional expenses. Selling expenses consist primarily of salaries, commissions and other related expenses for sales and marketing personnel, marketing, advertising and promotional expenses. General and administrative, or G&A, expenses increased $1.6 million in 2013 as compared to 2012 primarily related to increased compensation and outside services. G&A expenses consist primarily of salaries and other related expenses of administrative, executive and financial personnel and outside professional fees. In 2012 increases in selling expenses and increases in R&D expenses were partially offset by decreases in G&A expenses. R&D expenses increased $898,000 in 2012 as compared to 2011 primarily related to increased costs for compensation, supplies, travel and outside services. In 2012, selling expenses increased $369,000 primarily related to increased compensation, commissions and promotional expenses. G&A expenses decreased $592,000 in 2012 as compared to 2011 primarily related to decreased outside services. Our operating income for 2013 was $37.9 million, compared with $33.6 million in 2012 and $38.2 million in 2011. Operating income was 29 percent of revenues for 2013, 28 percent of revenues for 2012 and 32 percent of revenues for 2011. The increase in gross profit partially offset by the increase in operating expenses described above was the major contributor to the operating income increase in 2013 compared to the previous year. The decrease in gross profit and the increase in operating expenses described above were the primary contributors to the operating income decrease in 2012 compared to the previous year. Although we anticipate increases in R&D expenses and depreciation charges in 2014, we expect growth in our operating income during 2014 as compared to 2013. Income tax expense in 2013 totaled $12.7 million, compared with $11.4 million in 2012 and $13.4 million in 2011. The effective tax rates for 2013, 2012 and 2011 were 32.3 percent, 32.6 percent and 34.0 percent, respectively. The effective tax rate for 2013 benefitted from the extension of the federal research tax credit provisions included in the American Taxpayer Relief Act of 2012. The decrease in our effective tax rate for 2012 was primarily related to a favorable adjustment to an uncertain tax position related to income tax credits claimed for research and development following the conclusion of an Internal Revenue Service examination of our United States federal income tax returns for 2006, 2007 and 2008. Benefits from tax incentives for domestic production totaled $1.3 million in 2013, $949,000 in 2012 and $996,000 in 2011. Benefits from changes in uncertain tax positions totaled $195,000 in 2013, $720,000 in 2012 and $159,000 in 2011. We expect our effective tax rate for 2014 to be approximately 34.0 percent Management’s Discussion and Analysis of Financial Condition and Results of Operations ATRION 2013 ANNUAL REPORT 23 Liquidity and Capital Resources Effective October 1, 2011, our revolving credit facility with a money center bank was amended to increase the maximum principal amount of our revolving line of credit from $25.0 million to $40.0 million and to extend the date on which the lender is obligated to make advances under the revolving line of credit to October 1, 2016. The credit facility is to be utilized for the funding of operations and for major capital projects or acquisitions, subject to certain limitations and restrictions. Borrowings under the credit facility bear interest that is payable monthly at 30-day, 60-day or 90-day LIBOR, as selected by us, plus one percent. From time to time prior to October 1, 2016 and assuming an event of default is not then existing, we can convert outstanding advances under the revolving line of credit to term loans with a term of up to two years. We had no outstanding borrowings under our credit facility at December 31, 2013 or 2012. The credit facility contains various restrictive covenants, none of which is expected to impact our liquidity or capital resources. At December 31, 2013, we were in compliance with all financial covenants. We believe the bank providing the credit facility is highly-rated and that the entire $40.0 million under the credit facility is currently available to us. If that bank were unable to provide such funds, we believe such inability would not impact our ability to fund operations. At December 31, 2013, we had a total of $57.0 million in cash and cash equivalents, short-term investments and long-term investments, an increase of $12.4 million from December 31, 2012. The principal contributor to this increase was the cash generated by operating activities. Cash flows provided by operations of $36.6 million in 2013 were primarily comprised of net income plus the net effect of non-cash expenses. At December 31, 2013, we had working capital of $81.0 million, including $28.6 million in cash and cash equivalents and $18.4 million in short-term investments. The $31.4 million increase in working capital during 2013 was primarily related to increases in cash and cash equivalents, short-term investments and inventories partially offset by increases in accounts payable and accrued liabilities. The net increase in cash and cash equivalents was primarily related to the maturities of short-term investments. The increase in short-term investments was primarily related to the reclassification of long-term investments as their maturities became less than one year. Increased inventories are primarily related to higher safety stock levels necessary to support increased revenues. Increased accounts payable and accrued liabilities were primarily related to increased accrued compensation. Working capital items consisted primarily of cash, accounts receivable, short-term investments, inventories and other current assets minus accounts payable and other current liabilities. Capital expenditures for property, plant and equipment totaled $7.5 million in 2013, compared with $10.3 million in 2012 and $12.0 million in 2011. These expenditures were primarily for machinery and equipment. We expect 2014 capital expenditures, primarily machinery and equipment, to be greater than the average of the levels expended during each of the past three years. We paid cash dividends totaling $4.8 million, $24.5 million and $3.7 million during 2013, 2012 and 2011, respectively. In November 2012, our Board of Directors declared a special cash dividend of $10.00 per share on our outstanding common stock. This dividend which totaled $20.2 million was paid on December 10, 2012. We expect to fund future dividend payments with cash flows from operations. We purchased treasury stock totaling $9.2 million, $5.3 million and $1.5 million during 2013, 2012 and 2011, respectively. The table below summarizes debt, lease and other contractual obligations outstanding at December 31, 2013: Payments Due by Period Contractual Obligations Total 2014 2015– 2016 2017 and thereafter (in thousands) Purchase Obligations $ 13,460 $ 13,387 $ Total $ 13,460 $ 13,387 $ 64 $ 64 $ 9 9 24 ATRION 2013 ANNUAL REPORT Management’s Discussion and Analysis of Financial Condition and Results of Operations We believe our cash, cash equivalents, short-term investments and long-term investments, cash flows from operations and available borrowings of up to $40.0 million under our credit facility will be sufficient to fund our cash requirements for at least the foreseeable future. We believe our strong financial position would allow us to access equity or debt financing should that be necessary. Additionally, we expect our cash and cash equivalents and investments, as a whole, will continue to increase in 2014. From time to time, we accrue legal costs associated with certain litigation. In making determinations of likely outcomes of litigation matters, we consider the evaluation of legal counsel knowledgeable about each matter, case law and other case- specific issues. We believe these accruals are adequate to cover the legal fees and expenses associated with litigating these matters. However, the time and cost required to litigate these matters as well as the outcomes of the proceedings may vary from what we have projected. Off-Balance Sheet Arrangements We have no off-balance sheet financing arrangements. Impact of Inflation We experience the effects of inflation primarily in the prices we pay for labor, materials and services. Over the last three years, we have experienced the effects of moderate inflation in these costs. At times, we have been able to offset a portion of these increased costs by increasing the sales prices of our products. However, competitive pressures have not allowed for full recovery of these cost increases. New Accounting Pronouncements From time to time, new accounting standards updates applicable to us are issued by the Financial Accounting Standards Board (“FASB”), which we will adopt as of the specified effective date. Unless otherwise discussed, we believe the impact of recently issued standards updates that are not yet effective will not have a material impact on our consolidated financial statements upon adoption. Critical Accounting Policies The discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. In the preparation of these financial statements, we make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We believe the following discussion addresses our most critical accounting policies and estimates, which are those that are most important to the portrayal of our financial condition and results and require management’s most difficult, subjective and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Actual results could differ significantly from those estimates under different assumptions and conditions. We maintain an allowance for doubtful accounts to reflect estimated losses resulting from the failure of customers to make required payments. On an ongoing basis, the collectability of accounts receivable is assessed based upon historical collection trends, current economic factors and the assessment of the collectability of specific accounts. We evaluate the collectability of specific accounts and determine when to grant credit to our customers using a combination of factors, including the age of the outstanding balances, evaluation of customers’ current and past financial condition, recent payment history, current economic environment, and discussions with our personnel and with the customers directly. Accounts are written off when it is determined the receivable will not be collected. If circumstances change, our estimates of the collectability of amounts could be changed by a material amount. We are required to estimate our provision for income taxes and uncertain tax positions in each of the jurisdictions in which we operate. This process involves estimating our actual current tax exposure, including assessing the risks associated with tax audits, together with assessing temporary differences resulting from the different treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheet. We assess the likelihood that our deferred tax assets will be recovered from future taxable income and, to the extent we believe that recovery is more likely than not, do not establish a valuation allowance. In the event that actual results differ from these estimates, the provision for income taxes could be materially impacted. We assess the impairment of our long-lived identifiable assets, excluding goodwill which is tested for impairment as explained below, whenever events or changes in circumstances indicate that the carrying value may not be recoverable. This review is based upon projections of anticipated future cash flows. Although we believe that our estimates of future cash flows are reasonable, different assumptions regarding such cash flows or future changes in our business plan could materially affect our evaluations. No such changes are anticipated at this time. Management’s Discussion and Analysis of Financial Condition and Results of Operations ATRION 2013 ANNUAL REPORT 25 We assess goodwill for impairment pursuant to ASC 350, Intangibles—Goodwill and Other, which requires that goodwill be assessed whenever events or changes in circumstances indicate that the carrying value may not be recoverable, or, at a minimum, on an annual basis by applying a qualitative assessment on goodwill impairment to determine whether it is necessary to perform the two-step goodwill impairment test. During 2013, 2012 and 2011, none of our critical accounting policy estimates required significant adjustments. We did not note any material events or changes in circumstances indicating that the carrying value of long-lived assets were not recoverable. Quantitative and Qualitative Disclosures About Market Risks Foreign Exchange Risk We are not exposed to material fluctuations in currency exchange rates because the payments from our international customers are received primarily in United States dollars. Principal and Interest Rate Risk Our cash equivalents and short-term and long-term investments consist of money-market accounts and taxable corporate bonds. Our investment policy is to seek to manage these assets to achieve the goal of preserving principal, maintaining adequate liquidity at all times, and maximizing returns subject to established investment guidelines. In general, the primary exposure to market risk is interest rate sensitivity. This means that a change in prevailing interest rates may cause the value of and the return on the investment to fluctuate. Forward-looking Statements Statements in this Management’s Discussion and Analysis and elsewhere in this Annual Report that are forward looking are based upon current expectations, and actual results or future events may differ materially. Therefore, the inclusion of such forward-looking information should not be regarded as a representation by us that our objectives or plans will be achieved. Such statements include, but are not limited to, our expectations regarding our research and development expenditures in 2014, our depreciation charges in 2014, our 2014 effective tax rate, our focus on product development in 2014, the impact of the restrictive covenants in our credit facility on our liquidity and capital resources, our revenues and earnings in 2014, our growth in operating income in 2014, our 2014 capital expenditures, funding future dividend payments with cash flows from operations, availability of equity and debt financing, our ability to meet our cash requirements for the foreseeable future, our ability to fund operations if the bank providing our credit facility were unable to lend funds to us, the impact on our consolidated financial statement of recently issued accounting standards when we adopt those standards, payment of cash dividends in the future and increases in 2014 in cash, cash equivalents and investments. Words such as “expects,” “believes,” “anticipates,” “intends,” “should,” “plans,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward- looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel and the loss of any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. 26 ATRION 2013 ANNUAL REPORT Management’s Discussion and Analysis of Financial Condition and Results of Operations SELECTED FINANCIAL DATA (in thousands, except per share amounts) Operating Results for the Year ended December 31, Revenues Operating income Net income Depreciation and amortization Per Share Data: Net income per diluted share Cash dividends per common share Average diluted shares outstanding Financial Position at December 31, Total assets Long-term debt 2013 2012 2011 2010 2009 $ 131,993 $ 119,062 $ 117,704 $ 108,569 $ 100,643 37,944 26,582 8,592 13.18 2.40 2,017 33,626 23,629 7,610 11.66 12.10 2,027 38,168 26,038 6,544 12.82 1.82 2,031 30,977 20,952 7,041 10.32 10.56 2,030 25,004a 16,843a 7,163 8.36a 1.32 2,015 172,066 155,810 161,895 134,652 132,749 — — — — — a) Included a non-cash charge for the settlement of a pension plan termination that subtracted $1.0 million from operating income, $643,000 from net income and $0.32 from net income per diluted share. Selected Financial Data ATRION 2013 ANNUAL REPORT 27 NON-GAAP FINANCIAL MEASURES RECONCILIATION (Dollars in thousands) Included in our Annual Report is a non-GAAP financial measure that is calculated by excluding certain income and assets that are included in financial measures determined in accordance with GAAP. We have provided this non-GAAP measure as an additional tool for investors to evaluate the Company’s performance. This measure should be considered in addition to, rather than as a substitute for, GAAP measures of the Company’s performance. The table below provides a reconciliation of this non-GAAP financial measure with the most directly comparable GAAP financial measure. 2013 net income A Equity at December 31, 2012 Equity at December 31, 2013 Average equity B Return on equity (A/B) 1) 2013 after tax interest income. Adjustments 853 1 $ $ $ 44,614 2 56,979 3 $ $ $ $ GAAP 26,582 134,828 148,994 141,911 4 19% Non-GAAP $ $ $ $ 25,729 90,214 92,015 91,115 5 28% 2) Cash, cash equivalents and investments at December 31, 2012. 3) Cash, cash equivalents and investments at December 31, 2013. 4) GAAP equity at December 31, 2012 plus GAAP equity at December 31, 2013 divided by 2. 5) Adjusted equity at December 31, 2012 plus adjusted equity at December 31, 2013 divided by 2. 28 ATRION 2013 ANNUAL REPORT Non-GAAP Financial Measures Reconciliation Leadership Board of Directors Emile A Battat Chairman of the Board Atrion Corporation Hugh J. Morgan, Jr. Private Investor Former Chairman of the Board National Bank of Commerce of Birmingham Birmingham, Alabama Ronald N. Spaulding Private Investor Former President of Worldwide Commercial Operations Abbott Vascular Miami, Florida Corporate Information Corporate Office Atrion Corporation One Allentown Parkway Allen, Texas 75002 (972) 390-9800 www.atrioncorp.com Registrar and Transfer Agent American Stock Transfer and Trust Company, LLC Attn: Shareholder Services 6201 15th Avenue Brooklyn, NY 11219 Form 10-K A copy of the Company’s 2013 Annual Report on Form 10-K, as filed with the Securities and Exchange Commission, may be obtained by any stockholder without charge by written request to: Corporate Secretary Atrion Corporation One Allentown Parkway Allen, Texas 75002 Roger F. Stebbing President and Chief Executive Officer Stebbing and Associates, Inc. Signal Mountain, Tennessee John P. Stupp, Jr. President Stupp Bros., Inc. St. Louis, Missouri Executive Officers Emile A Battat Chairman of the Board David A. Battat President and Chief Executive Officer Jeffery Strickland Vice President and Chief Financial Officer, Secretary and Treasurer Stock Information The Company’s common stock is traded on the NASDAQ Global Select Market (Symbol: ATRI). As of February 25, 2014, there were approximately 3,300 stockholders, including beneficial owners holding shares in nominee or “street” name. The table below sets forth the high and low sales prices as reported by NASDAQ and the quarterly dividends per share declared by the Company for each quarter of 2012 and 2013. 2012 Quarter Ended High Low Dividends March 31 June 30 September 30 December 31 2013 Quarter Ended March 31 June 30 September 30 December 31 $ 261.98 $ 197.11 $ 0.49  235.70 226.99 223.00 High 195.78 202.01 185.16 Low 0.49  0.56  10.56 a  Dividends $ 210.99 $ 186.00 $ 0.56   222.74 261.00 299.00 186.37 217.00 252.50 0.56   0.64   0.64 The Company presently plans to pay quarterly cash dividends in the future. a) This amount includes a special cash dividend of $10.00 per share declared in the fourth quarter of 2012. 29 ATRION CORPORATION One Allentown Parkway, Allen, Texas 75002 972.390.9800 | www.atrioncorp.com 

Continue reading text version or see original annual report in PDF format above